Advertisement
------
Lilly Oncology to Unveil More Than 50 Studies at ASCO 2008
ALIMTA Lung Cancer Study Highlighting Key Histology Findings to Be Included in May 15 ASCO Live, Online Presscast
Advertisement
INDIANAPOLIS, May 1 /PRNewswire-FirstCall/ -- Eli Lilly and Company willunveil data from more than 50 studies at the 44th Annual Meeting of theAmerican Society of Clinical Oncology (ASCO) in Chicago, Ill. from May 30 toJune 3, 2008. The company will present the latest research findings onALIMTA(R) (pemetrexed for injection), GEMZAR(R) (gemcitabine HCl forinjection), and enzastaurin, an investigational, oral, targeted therapy. Themajority of the studies being presented are findings that support Lilly'sleadership in thoracic cancer research.
Of note is a pivotal Phase III study (ASCO Abstract # 8011) thatdemonstrated a key correlation between lung cancer histology (tissue type),treatment choice and patient outcome. It will be one of the studies featuredon Thursday, May 15 in ASCO's live online presscast. The virtual press eventwill be the first time ASCO has selected researchers to present key abstractsprior to its annual meeting.
"Improved patient outcomes via tailored therapy continues to be our focusand this year's ASCO is no exception," said Richard Gaynor, M.D., Lilly vicepresident, cancer research and global oncology platform leader. "With Lillystudies focusing on thoracic and breast cancer, among others, this meetingwill continue to show our commitment to answering the unmet needs of cancercare."
For more information on Lilly Oncology agents, including full prescribinginformation, please visit www.lillyoncology.com .
(Logo: http://www.newscom.com/cgi-bin/prnh/20080416/CLW066LOGO )Key Pemetrexed Abstracts for ASCO 2008: -- Abstract # 8011: June 2, 2008; 3:00 p.m. -- Maintenance pemetrexed plus best supportive care (BSC) versus placebo plus BSC: A phase III study -- This study will be featured during ASCO presscast on May 15 -- Abstract # 8096: June 1, 2008; 2:00 p.m. -- Comparison of patient outcomes stratified by histology among pemetrexed-treated patients with stage IIIB/IV NSCLC in two Phase II trials -- Abstract # 8097: June 1, 2008; 2:00 p.m. -- Resource utilization by non-small cell lung cancer histology: Results from the randomized, phase III trial of pemetrexed/cisplatin versus gemcitabine/cisplatin
SOURCE Eli Lilly and Company
